Saturday 17 October 2026
Export VREX’s income statement to Excel — free account
VAREX IMAGING
VREX Healthcare Medical Devices
VAREX IMAGING’s revenue for fiscal 2025 (year ended September 2025) was $844.6 million, up 4.14% from fiscal 2024. In the quarter to June 2026, revenue grew 3.69%, EPS grew 117.2%, free cash flow grew 757.1% and total debt fell 5.55%, each against the same quarter a year earlier.
18.41
0.06
−0.32%
Follow VREX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 19.68 |
P/S ratio |
0.61 | 0.57 | 0.52 | 0.51 | |
P/FCF ratio |
27.31 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
64.98 | (30.25) | (297.08) | 20.91 | |
P/B ratio |
1.06 | 0.99 | 0.91 | 0.86 | |
Price to Tangible BV |
1.87 | 1.75 | 1.61 | 1.46 | |
EV/Sales |
0.86 | 0.85 | 0.82 | 0.79 | |
EV/EBITDA |
7.56 | 7.32 | 7.70 | 6.80 | |
EV/Operating CF |
17.40 | 45.28 | (352.46) | 60.80 | |
EV/FCF |
38.60 | (54.81) | (22.89) | (34.01) | |
Quick Ratio |
1.67 | 1.67 | 1.21 | 1.30 | |
Current Ratio |
3.43 | 3.89 | 3.20 | 3.38 | |
Net Debt/EBITDA |
7.96 | 10.66 | 12.06 | 8.24 | |
Debt/Assets |
33.19% | 33.48% | 31.91% | 31.55% | |
Debt/Equity |
0.76 | 0.75 | 0.71 | 0.68 | |
Asset Turnover |
0.73 | 0.70 | 0.70 | 0.80 | |
Operating CF/Net income |
0.65 | (7.00) | 0.19 | 1.34 | |
Capex/Depreciation |
(0.79) | (1.47) | (0.87) | (1.23) | |
Interest Coverage |
2.48 | 1.95 | 0.84 | 3.93 | |
Research and Development Expense of Revenue |
10.57% | 10.35% | 10.28% | 11.07% | |
Selling, General and Administrative Expense of Revenue |
14.85% | 15.60% | 16.67% | 14.54% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
1.49% | 1.81% | 1.85% | 1.81% | |
Graham Net Nets |
0.04 | 0.05 | 0.05 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 12.03 | |
Earnings Yield |
(13.71%) | (13.99%) | (18.76%) | 5.08% | |
Free Cash Flow Yield |
3.66% | (2.73%) | (6.91%) | (4.60%) | |
Revenue per Share |
5.53 | 5.01 | 5.14 | 5.00 | |
Operating CF per Share |
0.19 | (0.39) | (0.04) | 0.50 | |
Capex per Share |
(0.14) | (0.26) | (0.15) | (0.21) | |
Free Cash Flow per Share |
0.06 | (0.64) | (0.18) | 0.29 | |
Cash per Share |
3.75 | 3.00 | 2.10 | 2.36 | |
Shareholders Equity per Share |
11.75 | 11.74 | 11.62 | 12.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.75 | 11.74 | 11.62 | 12.13 | |
Free Cash Flow |
2.30 | (26.80) | (7.70) | 12.00 | |
Working Capital |
454.60 | 470.60 | 430.30 | 445.70 | |
Capital Expenditures |
(5.60) | (10.70) | (6.20) | (9.00) | |
Net Current Asset Value |
21.00 | 26.40 | 24.30 | 43.60 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 9.52 | |
Capex to Sales |
0.02 | 0.05 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 6.08 | |
| Other line items | |||||
Average Receivables |
157.15 | 142.30 | 146.90 | 140.85 | |
Average Payables |
64.50 | 72.25 | 83.60 | 77.10 | |
Average Inventory |
282.10 | 303.95 | 315.70 | 322.90 | |
Average Assets |
1,160.50 | 1,215.10 | 1,223.50 | 1,086.70 | |
Average Common Equity |
514.90 | 522.50 | 526.00 | 490.00 |
Columns are period end dates